MAP2K7 and acute myeloid leukemia: While we observed a transient on-target activity of trametinib in a NRAS G12D-mutated AML patient, illustrating the dependency of AML cells to RAS mutations, results of early phases MEK inhibitors clinical trials found a limited efficacy of these molecules [25, 35, 52].